BLOOMFIELD HILLS - Zivo Bioscience, Inc. (OTCQB: ZIVO), a biotech/agtech company specializing in algal-based product candidates, has announced new findings from a 42-day study indicating its poultry feed product may improve broiler production efficiency. The study suggests that Zivo's product can reduce intestinal damage in chickens caused by coccidiosis, potentially offering an alternative to traditional antibiotics.
Coccidiosis, a disease caused by the Eimeria parasite, poses a significant economic burden to the poultry industry, with annual costs estimated between $10 billion and $17 billion. Current treatments largely depend on antibiotics or ionophores, with no major new technologies introduced in the last 60 years.
Zivo's product candidate has shown to not only decrease intestinal damage but also to enhance feed conversion ratios (FCR), a key profitability metric for poultry farms. The company's findings reveal that their product's impact on FCR is statistically significant when compared to untreated controls and comparable to the market-leading commercial ionophore.
John Payne, Chairman and CEO of Zivo Bioscience, expressed confidence in the product's potential to transform the industry by improving poultry outcomes and offering cost-effective solutions. The company anticipates that these results will expand discussions with potential partners in the agriculture and animal health sectors.
Zivo Bioscience focuses on developing therapeutic, medicinal, and nutritional products derived from proprietary algal cultures. Its intellectual property portfolio includes strains, biologically active molecules, production and cultivation techniques, and patented inventions for human and animal health applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.